Emerging utility of once-weekly exenatide in patients with type 2 diabetes
Authors Goud A, Zhong J, Rajagopalan S
Received 25 May 2015
Accepted for publication 29 August 2015
Published 21 October 2015 Volume 2015:8 Pages 505—512
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Prof. Dr. Ahmed R. G.
Peer reviewer comments 2
Editor who approved publication: Professor Ming-Hui Zou
Aditya Goud, Jixin Zhong, Sanjay Rajagopalan
Division of Cardiovascular Medicine, Department of Medicine, University of Maryland, Baltimore, MD, USA
Abstract: Type 2 diabetes mellitus (T2DM) is a major risk factor for the development of cardiovascular disease (CVD). Due to the ever increasing incidence of both T2DM and CVD and coexistence of these disorders, numerous agents have been developed over the years to target complications. We focus on the efficacy and safety perspective of a long-acting formulation of the glucagon-like peptide-1 analog exenatide. Our review focuses on the various landmark trials, efficacy, safety profile, and patient perspectives of weekly exenatide that delineates its current and future role in the treatment of patients with T2DM and CVD.
Keywords: incretin, glucagon-like peptide, hyperglycemia, glucose lowering
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]